Document Detail


The β-2 agonist debate: is there still a problem?
MedLine Citation:
PMID:  23037719     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: To present an evidence-based review of the US Food and Drug Administration (FDA) recommendations for long-acting β agonist (LABA) use in asthma. RECENT FINDINGS: The FDA recommendation contraindicating the use of LABAs without a concomitant asthma-controller medication such as an inhaled corticosteroid (ICS) is supported, with the caveat that concomitant use of an asthma-controller medication applies only to ICS therapy and not other asthma controller medications (such as leukotriene receptor antagonist therapy or theophylline). The recommendation that LABA therapy be stopped once asthma control is achieved is restrictive. Although downtitration of therapy should be considered in patients with asthma, who are well controlled, other options such as reducing the dose of ICS may be preferable to stopping LABA therapy. In patients who are at risk of unstable asthma or severe exacerbations, maintaining the ICS/LABA therapy without downtitration may be required. The recommendation against LABA use in patients whose asthma is adequately controlled with a low or medium dose ICS is supported. The recommendation that fixed-dose combination ICS/LABA products should be the only form in which LABAs are prescribed in adolescents and paediatric patients should be extended to all asthma patients. SUMMARY: The current β agonist debate focuses on the optimal management approaches for the use of LABA therapy to both minimize risk and maximize clinical efficacy.
Authors:
Mitesh Patel; Philippa Shirtcliffe; Richard Beasley
Related Documents :
22710579 - Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized...
24529449 - Air and surface contamination patterns of meticillin-resistant staphylococcus aureus on...
23560809 - Changed terms for drug payment influenced gps' diagnoses and prescribing practice for i...
8729159 - Routine perioperative dipyridamole 201tl imaging in diabetic patients undergoing vascul...
15755209 - The relapse rate in mb leprosy patients treated with 2-years of who-mdt is not low.
12682879 - Modern treatment strategies in polycythemia vera.
10619949 - Microvessel density in prostatic hyperplasia.
20825109 - Wireless emrs: patient data anytime, anywhere.
3403089 - Aztreonam in the treatment of serious gram-negative infections in the elderly.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-3
Journal Detail:
Title:  Current opinion in allergy and clinical immunology     Volume:  -     ISSN:  1473-6322     ISO Abbreviation:  Curr Opin Allergy Clin Immunol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100936359     Medline TA:  Curr Opin Allergy Clin Immunol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
aMedical Research Institute of New Zealand bCapital and Coast District Health Board, Wellington, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cost and logistics of alternative roll-out options for implementing human papillomavirus testing as ...
Next Document:  A Switchable Two-Photon Membrane Tracer Capable of Imaging Membrane-Associated Protein Tyrosine Phos...